Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children.
作者信息
von Hentig Nils, Angioni Carlo, Königs Christoph
机构信息
Internal Medicine II, HIVCENTER, Goethe University Hospital, Frankfurt, Germany.
Institute of Clinical Pharmacology, Goethe University Hospital, Frankfurt, Germany.
出版信息
South Afr J HIV Med. 2021 May 11;22(1):1222. doi: 10.4102/sajhivmed.v22i1.1222. eCollection 2021.
Abstract
摘要
相似文献
1
Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children.测定四种不同口服溶液中洛匹那韦/利托那韦的浓度，用于极年幼的HIV-1感染儿童的抗逆转录病毒治疗。
South Afr J HIV Med. 2021 May 11;22(1):1222. doi: 10.4102/sajhivmed.v22i1.1222. eCollection 2021.
2
Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.对414名接受含洛匹那韦/利托那韦的高效抗逆转录病毒治疗的罗马尼亚HIV感染儿童和青少年进行长期随访。
Pediatrics. 2007 May;119(5):e1116-20. doi: 10.1542/peds.2006-2802. Epub 2007 Apr 9.
3
Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.洛匹那韦利托那韦与一线和二线抗结核药物在治疗耐多药结核病的 HIV 感染儿童中的药代动力学和药物相互作用。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.00420-17. Print 2018 Feb.
4
Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.在科特迪瓦和布基纳法索，接受基于洛匹那韦/利托那韦的一线抗逆转录病毒疗法的2岁以下感染艾滋病毒儿童12个月期间的病毒学反应和耐药性：MONOD ANRS 12206队列研究
J Int AIDS Soc. 2017 Apr 25;20(1):21362. doi: 10.7448/IAS.20.01.21362.
5
ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.接受抗逆转录病毒治疗的HIV感染男性中ABCB1基因多态性与洛匹那韦和利托那韦在血液、精液及唾液中的浓度
Pharmacogenomics. 2009 Feb;10(2):311-8. doi: 10.2217/14622416.10.2.311.
6
Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.在接受过三类抗逆转录病毒药物治疗的人类免疫缺陷病毒1型感染儿童中，洛匹那韦/利托那韦治疗12个月时的安全性和抗病毒反应。
Pediatr Infect Dis J. 2005 Oct;24(10):867-73. doi: 10.1097/01.inf.0000180574.18804.90.
7
Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.洛匹那韦/利托那韦挽救疗法用于有蛋白酶抑制剂治疗史的HIV-1感染儿童后的病毒学阳性转归：一项前瞻性队列研究
J Antimicrob Chemother. 2004 Nov;54(5):921-31. doi: 10.1093/jac/dkh431. Epub 2004 Oct 7.
8
Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.利托那韦、奈非那韦及洛匹那韦/利托那韦在接受过抗逆转录病毒治疗的HIV感染儿童中的长期安全性和有效性
Pediatr Infect Dis J. 2008 May;27(5):431-7. doi: 10.1097/INF.0b013e3181646d5a.
9
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.在未接受过抗逆转录病毒治疗的 HIV-1 感染成人中，洛匹那韦和利托那韦联合拉米夫定双药治疗与洛匹那韦和利托那韦联合两种核苷类逆转录酶抑制剂三联治疗的随机、开放标签、非劣效性 GARDEL 试验的 48 周结果。
Lancet Infect Dis. 2014 Jul;14(7):572-80. doi: 10.1016/S1473-3099(14)70736-4. Epub 2014 Apr 27.
10
Simplifying antiretroviral therapy to lopinavir/ritonavir monotherapy did not improve quality of life and therapy adherence in pretreated HIV-infected children.将抗逆转录病毒疗法简化为洛匹那韦/利托那韦单一疗法并不能改善接受过治疗的HIV感染儿童的生活质量和治疗依从性。
AIDS Res Hum Retroviruses. 2014 Mar;30(3):260-5. doi: 10.1089/AID.2013.0204. Epub 2013 Dec 21.
本文引用的文献
1
Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.洛匹那韦/利托那韦的群体药代动力学：从婴儿期到成年期不同制剂和人体发育过程中的变化。
J Clin Pharmacol. 2018 Dec;58(12):1604-1617. doi: 10.1002/jcph.1293. Epub 2018 Sep 25.
2
Neurocognitive development in HIV-positive children is correlated with plasma viral loads in early childhood.感染艾滋病毒儿童的神经认知发育与幼儿期的血浆病毒载量相关。
Medicine (Baltimore). 2017 Jun;96(23):e6867. doi: 10.1097/MD.0000000000006867.
3
Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort.在科特迪瓦和布基纳法索，接受基于洛匹那韦/利托那韦的一线抗逆转录病毒疗法的2岁以下感染艾滋病毒儿童12个月期间的病毒学反应和耐药性：MONOD ANRS 12206队列研究
J Int AIDS Soc. 2017 Apr 25;20(1):21362. doi: 10.7448/IAS.20.01.21362.
4
Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.2000年至2014年期间，洛匹那韦-利托那韦暴露对西班牙马德里感染HIV-1的儿童和青少年的影响。
PLoS One. 2017 Mar 28;12(3):e0173168. doi: 10.1371/journal.pone.0173168. eCollection 2017.
5
Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.洛匹那韦/利托那韦与拉米夫定及阿巴卡韦或齐多夫定用于儿科固定剂量复方制剂的剂量比。
Antivir Ther. 2015;20(2):225-33. doi: 10.3851/IMP2876. Epub 2014 Oct 3.
6
Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.HIV暴露儿童和HIV感染儿童机会性感染的预防和治疗指南：美国国立卫生研究院、疾病控制与预防中心、美国传染病学会HIV医学协会、儿科传染病学会及美国儿科学会的建议
Pediatr Infect Dis J. 2013 Nov;32 Suppl 2(0 2):i-KK4. doi: 10.1097/01.inf.0000437856.09540.11.
7
Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.根据美国食品药品监督管理局（FDA）体重范围，儿童每日两次服用洛匹那韦/利托那韦片的药代动力学。
Pediatr Infect Dis J. 2014 Mar;33(3):301-5. doi: 10.1097/INF.0000000000000014.
8
The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program.国际抗逆转录病毒药物血浆测量实验室间质量控制计划：一项全球性的能力验证计划。
Ther Drug Monit. 2011 Apr;33(2):239-43. doi: 10.1097/FTD.0b013e31820fa528.
9
10
Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years.对出生至18岁儿童洛匹那韦药代动力学中体重、年龄和性别相关差异的群体分析。
Antimicrob Agents Chemother. 2006 Nov;50(11):3548-55. doi: 10.1128/AAC.00943-05. Epub 2006 Aug 28.
Zotero 插件